Researchers at the Biohub reported that co‑administering a tailored amino acid supplement dramatically improved lipid‑nanoparticle (LNP) uptake and performance for mRNA delivery and CRISPR editing in preclinical models. The team showed that physiological metabolic conditions reduced LNP uptake in cells, and supplementing with three common amino acids restored metabolic programs that favor nanoparticle internalization, increasing transfection and editing efficiency. The approach offers a low‑complexity, broadly applicable strategy to improve the translational gap between in vitro LNP performance and in vivo efficacy without reengineering the nanoparticle itself. Sponsors developing LNP‑based mRNA or gene‑editing therapeutics could adopt metabolic co‑formulation or dosing strategies to enhance potency and reduce dose requirements.